Maria Mariano
Overview
Explore the profile of Maria Mariano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
384
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pigliacelli F, Abril E, Cameli N, Iacovelli P, Mariano M
Dermatol Reports
. 2025 Mar;
17(1).
PMID: 40047294
Atopic dermatitis (AD) is a chronic inflammatory skin disease clinically characterized by eczematous skin manifestations. Sometimes, it can manifest with non-specific clinical features, which are common with other skin conditions,...
2.
Sivori F, Cavallo I, Truglio M, De Maio F, Sanguinetti M, Fabrizio G, et al.
Biofilm
. 2024 Oct;
8:100222.
PMID: 39381779
Atopic dermatitis (AD) is a chronic inflammatory skin disorder exacerbated by colonization. The specific factors that drive overgrowth and persistence in AD remain poorly understood. This study analyzed skin barrier...
3.
Iacovelli P, Pacifico A, Mariano M, Orsini D, DArino A, Pigliacelli F
Dermatol Reports
. 2024 Sep;
16(Suppl 2):9830.
PMID: 39295876
The most common cutaneous T-cell lymphoma, mycosis fungoides (MF), is clinically characterized by erythematous-violaceous nodules and erythematous-scaly patches. In the early stages of MF, phototherapy is currently the first line...
4.
Cavallo A, Camera E, Bottillo G, Maiellaro M, Truglio M, Marini F, et al.
Exp Dermatol
. 2024 Mar;
33(3):e15066.
PMID: 38532571
Atopic dermatitis (AD) is a composite disease presenting disruption of the skin permeability barrier (SPB) in the stratum corneum (SC). Recent evidence supports derangement of the sebaceous gland (SG) activity...
5.
Gori N, Sernicola A, Tolino E, Mariano M, Galluzzo M, Moretta G, et al.
J Dermatolog Treat
. 2023 Jul;
34(1):2230685.
PMID: 37400981
Objectives: The purpose of this study was to analyze the drug survival rate of dupilumab up to 2 years in a large real-world cohort of adult patients affected by moderate/severe...
6.
Napolitano M, Mariano M, Cristaudo A, Dastoli S, DI Guida A, DE Lucia M, et al.
J Dermatolog Treat
. 2022 Apr;
33(5):2670-2673.
PMID: 35435125
This study provides a comparative survival analysis between the only two drugs approved in Italy for the treatment of moderate-to-severe AD, cyclospoorin, and dupilumab. A multicenter, retrospective study, was performed...
7.
Cameli N, Silvestri M, Mariano M, Messina C, Nistico S, Cristaudo A
Dermatitis
. 2022 Mar;
33(2):110-115.
PMID: 35245221
Diabetes management has undergone many advances over the years, including the introduction of devices that allow patients to monitor blood glucose and administer insulin. Although these devices have improved patients'...
8.
Pigliacelli F, Pacifico A, Mariano M, DArino A, Cristaudo A, Iacovelli P
Int J Dermatol
. 2021 Nov;
61(3):377-378.
PMID: 34783020
No abstract available.
9.
Cavanna L, Citterio C, Biasini C, Madaro S, Bacchetta N, Lis A, et al.
Eur J Cancer
. 2021 Oct;
157:441-449.
PMID: 34601285
Introduction: Patients with cancer are presumed a frail group at high risk of contracting coronavirus disease (COVID-19), and vaccination represents a cornerstone in addressing the COVID-19 pandemic. However, data on...
10.
Silvestri M, Cristaudo A, Morrone A, Messina C, Bennardo L, Nistico S, et al.
Drug Saf
. 2021 May;
44(7):725-732.
PMID: 33959899
Three cyclin-dependent kinases 4/6, including palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer....